Drug Profile


Alternative Names: MK-8931; SCH-900931

Latest Information Update: 23 May 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antidementias; Fluorobenzenes; Pyridines; Small molecules; Thiadiazines
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 12 Apr 2017 Merck Sharp & Dohme completes a two-part phase I pharmacokinetics trial in USA (PO, Tablet) (NCT02910739)
  • 28 Feb 2017 Merck has patent protection for verubecestat in USA (Merck Annual report 2016)
  • 14 Feb 2017 Merck terminates the phase II/III EPOCH trial in Alzheimer's disease in Argentina, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Hungary, Italy, Japan, Netherlands, New Zealand, Portugal, Spain, South Korea, Turkey, USA and United Kingdom following the recommendation of the external Data Monitoring Committee (NCT01739348)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top